Clinical Trial: Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia

U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07270432) titled 'Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia' on Nov. 26.

Brief Summary: To evaluate the safety and efficacy of DNN.65.21.005 versus Combodart(R) in the treatment of benign prostatic hyperplasia

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Prostatic Hyperplasia, Benign

Intervention: DRUG: Product DNN.65.21.005

One capsule every 24 hours

DRUG: Combodart(R)

One capsule every 24 hours

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Ache Laboratorios Farmaceuticos S.A.

Disclaimer: Curated by HT Syndication....